Professional Documents
Culture Documents
DESCRIPTION
SYMPTOMS
NUMBERS
Hallucinations (~30-60 minutes) Worldwide AROUND 11% of
Increase in heart rate the population used ketamine
Increase in blood pressure in 2018 and between 2015
Unresponsiveness to stimuli and 2019, around 210,000
Involuntary rapid eye movement INDIVIDUALS 18 and over in
Dilated pupils the US reported ketamine use
Salivation within the past year. In clinical
Muscle stiffness trials for depression, over
41,000 PATIENTS were used to
Nausea
test the antidepressant effects
Cognitive difficulties
of the drug.
Unconsciousness
Amnesia
Ketamine is an allosteric
antagonist of NMDAR,
receptors in neurons
which are ligand and
voltage gated
(depolarizing to release
Mg+2) in order to
become permeable to
Na+, K+, and Ca+2,
acting as secondary
messengers. As ketamine
blocks GABA
interneurons (inhibitory),
disinhibits the glutamate
neurons, increasing the
transmission of
glutamate. As glutamate
increases, AMPA
receptors activate,
depolarizing the neuron
and allowing Ca+2 ions
to flow through voltage
gated ion channels. As
BDNF, known for its anti-
depressant effects, binds to receptor kinases, causing phosphorylation cascades to
eventually increase synaptic and dendritic spine density, associated with stress and
depression.
TREATMENTS
REAL-LIFE EXAMPLE